Linagliptin improved albuminuria but had no effect on eGFR and CV risk in patients with diabetes
In the CARMELINA trial nearly 10% of all patients with diabetes had nephrotic-range proteinuria at baseline. This was associated with a high incidence of cardiovascular/kidney disease but this secondary disease burden could not be lowered by linagliptin. The antidiabetes drug reduced albuminuria and HbA1c in all patients, but did not affect the cardiovascular (CV) risk over 2.2 […]
Continue Reading